Oruka Therapeutics
ORKA
143 hedge funds and large institutions have $1.6B invested in Oruka Therapeutics in 2025 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 54 increasing their positions, 16 reducing their positions, and 8 closing their positions.
475% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 8
238% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 16
83% more capital invested
Capital invested by funds: $876M → $1.6B (+$726M)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
36% more funds holding
Funds holding: 105 → 143 (+38)
13% more call options, than puts
Call options by funds: $527K | Put options by funds: $467K
12.47% less ownership
Funds ownership: 121.65% → 109.18% (-12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$47.7M |
| 2 |
BlackRock
New York
|
+$37.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$20.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.9M |
| 5 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$36.2M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$13.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.2M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$4.37M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.55M |
ORKA Hedge Fund Activity: Q4 2025 in Review
143 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2025, worth a combined $1.6B — up 83% from $876M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ORKA positions and 8 closed out — a net gain of 38 holders — while 54 added to existing stakes and 16 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $47.7M. The largest seller was Braidwell, cutting an estimated $36.2M.
- 143 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2025, up from 105 in Q3 2025.
- Funds reported $1.6B of Oruka Therapeutics stock for Q4 2025, up 83% quarter-over-quarter.
- 46 funds opened new Oruka Therapeutics positions in Q4 2025 and 8 closed out, a net change of +38 holders.
- The largest Oruka Therapeutics buyer in Q4 2025 was Paradigm Biocapital Advisors, an estimated $47.7M added.
- The largest Oruka Therapeutics seller in Q4 2025 was Braidwell, an estimated $36.2M sold.
Based on aggregated 13F filings for Q4 2025.